BCR and B-cell chronic lymphocytic leukemia: The authors found that miR-34a is usually upregulated during DDR in CLL cells during FCR (Fludarabine, Cyclophosphamide, Rituximab) therapy; in this process, miR-34a downregulates the transcription factor Forkhead box P1 (FOXP1), thus limiting its ability to stimulate BCR signaling; the authors also demonstrated that low levels of miR-34a could be used as a biomarker of poor response in CLL patients treated with FCR [62].